NCT04047290已完成1 期
A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 80
- 试验地点
- 7
- 主要终点
- Incidence and nature of participants with adverse events (AEs)
研究概览
简要总结
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumor malignancies. The study consists of a dose escalation phase (Phase 1a) to determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for AK112 as a single agent, and a dose expansion phase (Phase 1b) in subjects with specific tumor types which will characterize treatment of AK112 as a single agent at the MTD or RP2D.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written and signed informed consent and any locally required authorization obtained from the subject/legal representative.
- •In dose-escalation cohorts (Phase 1a), histologically or cytologically documented advanced or metastatic solid tumor that is refractory/relapsed to standard therapies, or for which no effective standard therapy is available, or the subject refuses standard therapy.
- •In the dose-expansion cohorts (Phase 1b), histologically or cytologically confirmed selected advanced solid tumors.
- •Subject must have at least one measurable lesion according to RECIST Version1.
- •Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or
- •Available archived tumor tissue sample to allow for correlative biomarker studies. If unavailable or unsuitable, the subject must consent and undergo fresh tumor biopsy.
- •Adequate organ function.
- •Subjects with central nervous system (CNS) metastases must have been treated, be asymptomatic.
- •Females of childbearing potential and non-sterilized males who are sexually active must use an effective method of contraception from screening until 120 days after final dose of investigational product or women of non child bearing potential.
- •Life expectancy ≥12 weeks.
排除标准
- •History of severe hypersensitivity reactions to other mAbs.
- •Prior malignancy active within the previous 3 years except for the tumor for which a subject is enrolled in the study, and locally curable cancers that have been apparently cured, (e.g. basal cell skin cancer, or carcinoma in situ of the cervix or breast).
- •For subjects enrolled in the dose escalation phase, having received prior anti-PD-1, anti-PD-L1, anti-CTLA-4 or any other immunotherapy or immune-oncology (IO) agent within 28 days of commencing treatment with AK112 or experienced a toxicity that led to permanent discontinuation of prior immunotherapy. All AEs while receiving prior immunotherapy have not completely resolved or resolved to Grade 1 prior to screening, required the use of additional immunosuppression other than corticosteroids
- •Receiving any immunotherapy, conventional or investigational systemic anticancer therapy within 4 weeks prior to the first dose
- •Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment (hormones use for non-cancer related conditions is acceptable).
- •Subjects with clinically significant cardiovascular disease
- •Subjects with a condition requiring systemic treatment with either corticosteroid (> 10 mg daily ) or other immunosuppressive medications within 2 weeks of study drug administration.
- •Current or recent use of aspirin (> 325 mg/day) or treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol.
- •Current unstable of full-dose oral or parenteral anticoagulants or thrombolytic agents for > 2 weeks prior to the first dose of AK112
- •Active or prior documented autoimmune disease within the past 2 years or conditions not expected to recur in the absence of an external trigger)
- •Active or prior documented inflammatory bowel disease
- •History of primary immunodeficiency.
- •History of organ transplant.
- •Known allergy or reaction to any component of the AK112 formulation.
- •History of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies.
- •Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1
- •Major surgical procedure within 30 days prior to the first dose of AK112 or still recovering from prior surgery.
- •Known history of HIV.
- •Known active hepatitis B or C infections. Note: Subjects with HCC and positive HBsAg result are eligible if the subjects were treated with antiviral therapy and HBV viral load less than 500 IU/mL prior to first dose of AK
- •An active infection requiring systemic therapy
- •Received live attenuated vaccination within 30 days prior to the first dose of AK112.
研究组 & 干预措施
AK112
Experimental
AK112 IV every 2 weeks (q2w) or every 3 weeks (q3w)
干预措施: AK112 (Drug)
结局指标
主要结局
Incidence and nature of participants with adverse events (AEs)
时间窗: From time ICF is signed until 90 days after last dose of AK112
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Number of participants with DLTs
时间窗: During the first four weeks of treatment with AK112
DLTs will be assessed during the dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle (4 weeks) of treatment.
次要结局
- Overall survival (OS)(Up to 2 years)
- Number of subjects who develop detectable anti-drug antibodies (ADAs)(From first dose of AK112 through 90 days after last dose of AK112)
- Objective response rate (ORR)(Up to 2 years)
- Disease control rate (DCR)(Up to 2 years)
- Progression-free survival (PFS)(Up to 2 years)
- Area under the curve (AUC) of AK112 for assessment of pharmacokinetics(From first dose of AK112 through 90 days after last dose of AK112)
- Maximum observed concentration (Cmax) and Minimum observed concentration (Cmin) of AK112(From first dose of AK112 through 90 days after last dose of AK112)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
1 期
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid TumorsAdvanced CancerNCT03352531Akesobio Australia Pty Ltd99
已完成
1 期
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid TumorsAdvanced CancerNCT03261011Akesobio Australia Pty Ltd119
已完成
早期 1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid TumoursAdvanced or Metastatic Solid TumoursNCT05021120Akesobio Australia Pty Ltd67
Unknown
1 期
A Clinical Trial to Evaluate Clifutinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia(AML)Acute Myeloid LeukemiaNCT04827069Sunshine Lake Pharma Co., Ltd.80
已完成
1 期
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsSolid TumorsNCT04774952Revolution Medicines, Inc.58